Synairgen plc Update on LOXL2 programme with Pharmaxis (3723N)
January 17 2019 - 3:31AM
UK Regulatory
TIDMSNG
RNS Number : 3723N
Synairgen plc
17 January 2019
Press release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces positive progress on LOXL2 programme by
Pharmaxis
Pharmaxis reports LOXL2 programme now Phase II ready following
completion of 13 week toxicity studies
Pharmaxis ready to progress commercial partnering
discussions
Southampton, UK - 17 January 2019: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, is pleased to
note that Pharmaxis has reported receipt of all data for the LOXL2
inhibitor candidates in three-month toxicity studies. These data
complete the overall package required for Pharmaxis' partnering
discussions.
In November 2018 Pharmaxis announced the successful completion
of the Phase I single and multiple ascending dose trials of their
two LOXL2 inhibitor compounds. Data from the Phase I trials support
once daily oral dosing and demonstrated best-in-class inhibition of
the LOXL2 enzyme. Together with preclinical data in models of
fibrosis, this package shows the potential of these compounds to
target diseases associated with LOXL2 such as Non--alcoholic
Steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
Full details of the Pharmaxis announcement can be found at
www.pharmaxis.com.au/assets/Documents/pdf/02019/ASX/2019-01-16-LOXL2-phase-2-ready.pdf
Richard Marsden, Chief Executive Officer of Synairgen, said:
"The successful completion of the longer term toxicology studies
completes the data set. Pharmaxis is now conducting a final series
of scientific briefings to potential partners. In accordance with
the amended collaboration agreement with Pharmaxis, Synairgen will
receive circa 17% of any future net partnering proceeds from all
fibrotic indications for the LOXL2 inhibitors. We are really
pleased about this positive development and look forward to further
updates from Pharmaxis."
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott / Sue Stuart / Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into
clinical development. The BioBank of human samples is used in
these models to increase confidence in the likelihood of successful
drug development.
Synairgen is currently running a two-part Phase II trial
evaluating SNG001, the Company's wholly-owned inhaled interferon
beta (IFN-beta) therapeutic candidate. The Phase II trial, called
SG015, has been designed to assess the safety of SNG001
in COPD patients and its clinical benefit in these patients when
they have a cold or flu infection, a major driver of COPD
exacerbations.
Core to Synairgen's business strategy is the realisation of
value via licensing transactions. In August 2015 the Company
entered into a collaboration with Pharmaxis to develop an oral
LOXL2 inhibitor to reduce fibrosis in patients with idiopathic
pulmonary fibrosis (IPF). In December 2017 the collaboration
agreement was amended as Pharmaxis took on full responsibility for
the programme, with Synairgen receiving a GBP5 million upfront
payment and circa 17% of any future net partnering proceeds from
all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen,
please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFESAWFUSEEF
(END) Dow Jones Newswires
January 17, 2019 03:31 ET (08:31 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2024 to Jun 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Jun 2023 to Jun 2024